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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Overexpression of delta-like 4 induces arterialization and attenuates vessel
formation in developing mouse embryos
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The importance of Notch signaling pathway
in the regulation of vascular development
and angiogenesis is suggested by the ex-
pression of Notch receptors and ligands in
vascular endothelial cells (ECs) and the
observed vascular phenotypes in mutants
of Notch receptors or ligands, especially
Dll4. DLL4 is specifically expressed in arte-
rial ECs during development, and haplo-
insufficiency is embryonically lethal in mice.
To address the role of Dll4 in vascular devel-
opment, we produced mDll4 conditionally
overexpressed transgenic mice that were
crossed with constitutive recombinase cre
lines. Double transgenic embryos displayed
grossly enlarged dorsal aortae (DA) and
died before embryonic day 10.5 (E10.5),
showing a variable degree of premature
arteriovenous fusion. Veins displayed ec-
topic expression of arterial markers. Other
defects included reduced vascular sprout-
ing, EC proliferation, and migration. mDll4
overexpression also inhibited VEGF signal-
ing and increased fibronectin accumulation
around the vessels. In vitro and in vivo
studies of DLL4-FL (Dll4–full-length) in ECs
recapitulate many of the mDll4 transgenics
findings, including decreased tube forma-
tion, reduced vascular branching, fewer ves-
sels, increased pericyte recruitment, and
increased fibronectin expression. These re-
sults establish the role of Dll4 in arterial
identity determination, and regulation of an-
giogenesis subject to dose and location.
(Blood. 2008;112:1720-1729)
Introduction
Arterial versus venous differentiation has long been thought to be
mainly dependent on physical factors such as blood pressure and
oxygen concentration. Recently, however, the identification of
several genes that are specifically expressed in arterial or venous
endothelial cells (ECs) well before the onset of circulation seems to
indicate an important role for genetic determination of ECs in the
primary differentiation events between arteries and veins. Among
these genes are Eph-B4, specifically expressed in venous ECs1-3
and Ephrin-B2,1,3,4 Notch1,5 Notch46 and Dll47, among others,
which are specifically expressed in arterial ECs.
Dll4 is the only Notch ligand known to have an expression
pattern similar to Notch1 and Notch4 in the vascular system, being
likewise restricted to the arterial endothelium. Mutation studies in
zebrafish have shown that Notch homologues are the earliest genes
expressed in an endothelial arterial specific fashion and regulate
arterial and venous endothelial differentiation downstream of
vascular endothelial growth factor (Vegf) and sonic-hedgehog
(Shh) and upstream of the ephrin pathway.8 There is growing
evidence, in both zebrafish and mouse, that Notch function is
essential in the establishment of the arterial endothelial cell fate.8-10
In this context, the ligand Dll4, given its arterial specific expression
pattern and striking loss-of-function phenotype10 appears to play a
pivotal role.
In the present study we investigated the role of Dll4 in mammalian
vascular development by producing and characterizing murine gain-of-
function mutants. To achieve generalized overexpression of mDll4, we
produced conditional transgenic mouse lines, ZEG-Dll4, which when
crossed with a constitutive cre line, CAG-Cre mice,11 express the native
form of Dll4 under the control of the chick beta actin promoter and
cytomegalovirus (CMV) enhancer. Whole-body mDll4 gain-of-function
causes a profound phenotype in the developing vasculature, enhancing
the arterial phenotype, fusion of large arteries and veins, enlarged
arteries with excess fibronectin accumulation, and decreased vessel
branching. A second transgenic line of endothelial cell specific Dll4
expression resulted in similar phenotype. Dll4 dose and location are
critical for proper vessel formation, as either gain- or loss-of-function
leads to profound vascular defects. Dll4 overexpression was also studied
using in vitro and in vivo angiogenesis models recapitulating the
findings in mutant mouse, which are reversed by the administration of a
soluble form of Dll4.
Methods
Generation of conditional mDll4 gain-of-function mice
The study, project number CVT49766, was approved by the Faculty of
Veterinary Medicine of Lisbon Ethics and Animal Welfare Committee. The
mouse Dll4 cDNA was cloned into the pZ/EG transgenic vector (Figure
1A),12 a generous gift of Dr Corrine Lobe (Sunny Brook Health Science
Centre, Toronto, ON), which contains a CMV enhancer/chick beta-actin
promoter to drive strong constitutive expression of downstream coding
sequences, along with 2 reporters, floxed beta-geo, 3x polyA and IRES-
GFP. The mDll4 cDNA was inserted downstream of the floxed beta-geo 3x
polyA. Therefore, the transgenic expression of beta-geo signals the
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presence of the nonrecombined vector, whereas Dll4 and EGFP coexpres-
sion occurs on cre recombination. The vector was linearized with SfiI and
BsaI and electroporated into R1 ES cells, transgenic clones were selected by
incubation for 7 days in G418 containing media, aggregated with CD1
morulae and transferred into pseudo-pregnant CD1 females. Chimeric
males were crossed with CD1 females and the agouti progeny was screened
for germ line transmission of the transgene based on lacZ staining analysis
of tail biopsy samples. Founder lines were characterized for embryonic lacZ
expression and those 2 with the strongest and most widespread expression
were selected. Both lines displayed identical phenotypes when crossed with
a constitutive chicken beta-actin cre (CAG-cre) transgenic mouse line.11
The TetO7-Dll4 transgenic construct was produced by cloning the mouse
Dll4 cDNA into p(tetO7)-CMV-bGH,13 a generous gift of Dr J. A. Whitsett
(Cincinnati Childrens Hospital Medical Center, Cincinnati, OH). This
construct was used in pronuclear microinjection to generate Dll4 condi-
tional overexpression transgenics. Two different founders were obtained,
displaying identical phenotypes when crossed with the tie2-rtTA-M2
transgenic line, a kind gift of Dr Urban Deutsch (Theodor Kocher Institute,
Berne, Switzerland). Transgene expression induction was achieved by
administration of doxycycline at 2 mg/mL in drinking water, with 4%
sucrose, to pregnant females from E5.5 until the day of sacrifice. Animal
studies were performed with approval from the institutional ethics committee.
In situ hybridization and immunohistochemistry
Whole-mount immunohistochemistry and lacZ staining was carried out by
standard techniques.13 Antibodies were from Pharmingen (San Jose, CA;
PECAM1/CD31) and (Sigma-Aldrich, St Louis, MO; SMA, fibronectin, and
laminin). Digoxigenin-labeled RNA probes were transcribed from linearized
templates, and in situ hybridization of cryosections was carried out as previously
described.15 Probe sizes were as follows: EphrinB2, 700 bp; Eph-B4, 1466 bp;
Flk1, 800 bp; Connexin37, 978bp; Notch1, 2168 bp; Hey1, 2215 bp.
Tissues were processed using standard methods.13 Sections were incubated
with primary antibody overnight at 4°C and appropriate secondary antibody for
1 hour at room temperature. Antibody binding was localized with ABC staining
kit from Vector Laboratories and peroxidase activity detected using diaminoben-
zidine substrate solution (Vector Laboratories, Burlingame, CA). The positive
staining area was estimated using ImageJ and analyzed by Student t test.
Fluorescent immunostaining was performed in a similar fashion.Appropriate
fluorescein-conjugated secondary antibodies (Sigma-Aldrich) were used and
nuclei were counterstained with 4, 6-diamidino-2-phenylindole dihydrochloride
hydrate (DAPI; Molecular Probes, Eugene, OR). Images were obtained using an
Olympus AX70 fluorescence microscope and Spot version 2.2.2 (Diagnostic
Instruments, Sterling Heights, MI) digital imaging system
In vivo proliferation assay
Pregnant females were injected with 100 g BrdU per gram of live weight
2 hours before being humanely euthanized. Frozen sections were stained first
with PECAM1/CD31 antibody, followed by antibodies against BrdU (Sigma-
Aldrich), as previously described.16 Appropriate fluorescent secondary antibodies
(Molecular Probes) were used and sections were counterstained with DAPI.
Microangiography
Ink injections were carried out in E9.0 embryos. Briefly, embryos were dissected
in phosphate-buffered saline (PBS)–Tween (0.1%) and immediately injected in
the outflow tract of the heart with India ink diluted in PBS-Tween to 20%, using
glass micropipettes. Embryos were photographed directly.
Figure 1. mDll4 overexpression causes major de-
fects in the developing vascular system. (A) pZ/EG-
mDll4 transgenesis vector and result of Cre recombina-
tion. (B) LacZ staining of a ZEG-Dll4 embryo at embryonic
day 8.0 (E8.0). (C) EGFP expression in the double
transgenic (DT) embryos at E8.5. (D) Haemorrhaging in
the DT embryos at E9.0. Whole-mount PECAM1 immuno-
staining of E9.0 DT (E) and control (F) embryos. (F) DT
embryo at E9.0 showing a hypertrophied dorsal aorta
(red arrow), ramified ACV (green arrow), and an un-
branched vascular plexus in the head region (blue
arrow), relative to the control embryo (E). PECAM1
immunostaining of vitelline membranes from WT (G) and
DT embryos (H) show a blockage in the angiogenic
remodeling of the vitelline vasculature of mutant em-
bryos. (I,J) Serial sections of an E9.5 WT embryo demon-
strating the region where the ACV (green arrow) con-
nects to the sinus venosus (blue arrow; K-M) Serial
sections of a E9.5 DT embryo (anterior-posterior) show-
ing a fusion between the aorta (red arrow) and the ACV
(green arrow) just before its connection to the sinus
venosus (blue arrow). In panel K the ACV consists of a
plexus of small capillaries (green arrow) that join to form
a single vessel with a large lumen just before its fusion
with the dorsal aorta (M). Microangiography with India
Ink injection confirmed the existence of functional connec-
tions between the DA and the ACV of DT embryos (O),
with ink flowing directly from the aortae (red arrow) to the
sinus venosus (blue arrow), in contrast to the regular flow
of the control embryos (N). Endothelial-specific overex-
pression of mDll4 (Dll4e) causes the same vascular
defects as observed in DT embryos. (P) Immunofluores-
cence with anti-PECAM1 and anti-Dll4 antibodies on WT
embryo at E9.5. Immunofluorescence with anti-PECAM1
and anti-Dll4 antibodies on DT embryo (Q,R) and Dll4e
embryos at E9.5 (S,T), confirming that Dll4 is ubiqui-
tously expressed in DT embryos and that it is pan-
endothelial in Dll4e embryos, while WT embryos show
only Dll4 expression on the dorsal aortae (DA).
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Fluorescence-activated cell sorting purification of embryonic
ECs and RNA preparation
Nine to 12 somite control and double transgenic (DT) embryos were
dissected free of extraembryonic membranes, digested in 0.1% Collagenase
III (Worthington, Lakewood, NJ), and resuspended in cold 10% FCS in
HBSS. The cells were then blocked in 5% rat serum and stained with
allophycocyanin-labeled anti-PECAM1/CD31 antibody (Pharmingen) at
1:400 dilution. Viable cells were gated by their forward and side scatter
characteristics, and gates were set to sort cell population positive for GFP
and PECAM1/CD31 in double transgenic embryos, or only PECAM1/
CD31 positive in control embryos. Total RNA was extracted from both cell
populations using the RNeasy MiniKit (Qiagen, Valencia, CA).
Cell culture
Healthy human umbilical vein endothelial cells (HUVECs) were obtained
from Cambrex (Walkersville, MD) and maintained in EGM2-supplemented
medium (Invitrogen, Carlsbad, CA). For all experiments, HUVECs were
used at passages 4 or below. The 293 cell line was obtained from ATCC
(Manassas, VA) and cultured under recommended conditions.
Dll4 construct, transfection, cell sorting, and analysis
Full-length human Dll4 gene was cloned by polymerase chain reaction
(PCR) amplification from human cDNA (Clontech, Mountain View, CA)
made from fetal lung tissue (amino acid residues 1-685) was expressed
from pcDNA3.1 expression vector (Invitrogen) as previously described.17
Typically, HUVECs were transiently transfected with full-length Dll4 or
vector alone. For sorting transfected cells, the MACSelect 4.1 selection kit
(Miltenyi Biotech, Auburn, CA) was used as per manufacturer’s instruc-
tions and previously described.17 Selection efficiency was confirmed by
immunostaining using Dll4 monoclonal antibody. Cell proliferation assay
and apoptosis assays were performed as previously described.17,18
Endothelial cell tube formation assay
Matrigel (250 L; BD Biosciences, Palo Alto, CA) was placed in each well
of 24-well plate and allowed to polymerize as described.17 HUVECs in
EGM2 medium were plated at a concentration of 104 cells/well with test
material at various concentrations in triplicates, and pictures were taken at
various time points using a Bioquant Image Analysis system (Nashville,
TN). Length of cords formed and number of junctions was measured using
ImageJ software (National Institutes of Health [NIH], Bethesda, MD).
Experiments were repeated twice.19
Murine Matrigel plug angiogenesis assay
In vivo angiogenesis was assayed using the Matrigel plug assay as
previously described.17 Matrigel (8.13 mg/mL)) was mixed with test
compounds at 4°C and 0.5 mL was injected into the abdominal subcutane-
ous tissue of female Balb/C nu/nu mice (5 mice per group). Plugs were
recovered on day 6 and processed for immunohistochemical analysis. To
study the effect of full-length DLL4, 106 293T transfected (vector alone or
full-length DLL4) and sorted cells were placed in VEGF containing
Matrigel for plug assays. Vascular identity of the infiltrating cells was
established with PECAM/CD31 immunostaining. The experiment was
repeated 3 times. The vascularized area in each section was calculated
using ImageJ (NIH).
Quantitative transcriptional analysis
Real-time PCR analysis was performed on sorted ECs from wild-type (WT)
and DT embryos or from 2 separate samples obtained from whole embryo
lysates of WT and DT embryos. Gene expression was normalized to -actin.
For in vitro studies total RNA extracted from HUVECs transfected with vector
and full-length Dll4 for reverse transcription (RT)–PCR with specific primers for
Dll4, GAPDH, -actin, Notch1, Notch4, VEGFR2, Hey1, Hey2, Hes1, Hes2,
fibronectin, laminin, PDGF, and PDGFRB as previously described.17 Primer
pairs used in this study are available on request.
Results
mDll4 overexpression caused embryonic death at around
E9.0 to E9.5
Two founder mouse lines were generated using the following constructs
(Figure 1A) that displayed strong and ubiquitous expression of lacZ
(Figure 1B). Both of these lines produced a similar phenotype when
crossed with the CAG-Cre mouse line, and one of these lines, referred to
as Z/EG-Dll4 from here on, was used for further studies. Crossing
Z/EG-Dll4 with endothelial-specific Cre lines, like Tie2-Cre,20 Tie1-
Cre21 or Flk1-Cre,22 produced no detectable embryonic vascular pheno-
type. Analysis of GFP expression, as a reporter of effective recombina-
tion by Cre, revealed that at E9.0 only 12% of ECs were GFP-positive
(Figure S1B,C, available on the Blood website; see the Supplemental
Materials link at the top of the online article). Alternatively, crossing
Z/EG-Dll4 with CAG-cre led to in utero death of DT embryos (n 46).
The DT embryos dissected at E8.0 to E9.5 constitutively expressed GFP
(Figure 1C), which indicated that cre recombination of the Z/EG-Dll4
conditional vector was occurring in all cells of the embryo, eliminating
geo expression by excision of the floxed cassette and allowing
coexpression of Dll4 and GFP, through an IRES element. By E9.0 these
DT embryos displayed extensive hemorrhaging throughout the body,
and pericardial effusion, along with failure to close the neural tube in the
cephalic region (Figure 1D). No live DT embryos were recovered after
E10.5 (data not shown; n 34).
mDll4 overexpressing embryos displayed vascular defects
Whole-mount PECAM/CD31 immunostaining of E9.0 DT em-
bryos revealed grossly dilated DA, ramification of the anterior
cardinal vein (ACV), dilated heart and pericardium (Figure 1E,F).
Vitelline vasculature of DT embryos did not remodel from the
honeycomb shaped primary vascular plexus which persisted until
the death of the embryo (Figure 1G,H). PECAM1/CD31 immuno-
staining of cross-sections of the DT mDll4 overexpression embryos
showed fusion between the ACV and the DA leading to the
formation of a bypass circulation from the DA to the sinus venosus
region of the heart (Figure 1K-M). The ACV appeared branched in
most of the trunk (Figure 1K), and progressing to single luminal
vein (Figure 1L) just before fusing with the dorsal aorta and the
sinus venosus (Figure 1M). India ink microangiography showed
short circuit of perfusion between outflow and inflow tracts of the
heart resulting from proximal fusion of arterial and venous
compartments leading to reduced blood flow to the rest of the
embryo (Figure 1N,O).
Cardiovascular phenotype caused by endothelial-specific
mDll4 overexpression is identical to that caused by ubiquitous
mDll4 overexpression
As the analysis of endothelial-specific overexpression was revealed to
be impossible with the ZEG-Dll4 mouse line, we decided to produce a
different conditional Dll4-overexpressing transgenic mouse line. This
was intended to determine whether the observed phenotypic changes
were a specific consequence of endothelial Dll4 overexpression or the
outcome of generalized overexpression of Dll4. The TetO7-Dll4 mouse
lines were crossed with Tie2-rtTA-M2 mice and DT embryos were
analyzed at E8.5-E9.5. Induction started at 5.5 days postcoitus (dpc),
2 days earlier than the start of endogenous Dll4 expression, to allow for
doxycycline saturation of the embryos to be achieved slightly earlier
than the start of endogenous Dll4 expression. Dll4 immunostaining at
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E9.0 showed marked endothelial-specific overexpression of mDll4
(Figure S1F,G). The endothelial-specific mDll4 overexpressing em-
bryos were growth-retarded and died at E10.5, exhibiting the same
vascular defects as the DT embryos (Figure 1S,T).
mDll4 overexpression alters cardiac morphogenesis
Cardiac defects in DT embryos can be characterized by reduced
myocardial trabeculation in the ventricles (Figure 2A,B), atrial
distention (Figure 2C,D), and absence of cells within the outflow
tract cushions (Figure 2E,F). In DT embryos, cardiomyocites
accumulate at the periphery of the ventricles, failing to enter the
trabeculations (Figure 2G,H). In DT embryos the first branchial
arch artery is formed, showing roughly the same diameter as the
DA, but the second branchial arch artery is severely reduced or
absent from these embryos until their death (Figure 2I,J).
mDll4 overexpression confers arterial phenotype to all ECs
The Notch1 and Hey123 genes, which are normally expressed specifi-
cally in the arterial endothelium, are expressed in the DT embryos both
the DA and the ACV (Figure 3A,B,D,E). The ectopic expression of
Hey1 in DT embryos represents activation of Notch signaling in theACV.
The arterial specific endothelial markers EphrinB2 and Connexin37 are
expressed in both the DA and the ACV of DT embryos, confirming the
establishment of the arterial cell identity in the venous compartment of the
mutant embryos (Figure 3G,H,J,K). Separation of the arterial and venous
vascular beds appears to be dependent on the expression of EphrinB2 in
arteries and EphB4, the cognate receptor for EphrinB2, in veins. The
venous marker EphB4 is down-regulated in the DT embryos, indicating
loss of endothelial venous identity (Figure 3I,L). VEGF receptor Flk1/
VEGFR2 is normally expressed on all ECs; however, its expression was
reduced in mDll4 transgenic mutants (Figure 3C,F).
Endothelial cell migration and intersomitic vessel formation is
impaired in mDll4 overexpressing embryos
Enlargement of DA in the mDll4 overexpressing embryos could
result from increased endothelial cell proliferation. To test this
hypothesis we analyzed the DT and WT embryos for BrdU
incorporation and apoptosis. BrdU incorporation was reduced by
43% in arterial ECs in the DT embryos, compared with the WT
(Figure 4A), while the number of ECs per aortic cross-section was
Figure 2. mDll4 overexpression causes morphogenetic defects in the developing heart. PECAM1 immunostaining of cryosections from E9.5 WT and DT embryos
(A) WT heart ventricle (v) showing normal trabeculation. (B) DT heart ventricle (v) revealing reduced trabeculation. (C) WT heart atria (a). (D) DT heart atria (a) revealing gross
hypertrophy. (E) Outflow tract of heart from WT embryo. (F) Outflow tract of heart from DT embryo, showing acellularization of the outflow tract cushions (*). SMA
immunostaining of cryosections from E9.5 WT and DT embryos (G) heart ventricle (v) of WT embryo. (H) Heart ventricle (v) of DT embryo showing aggregation of
cardiomyocites at the periphery of the ventricle and irregular distribution of cardiomyocites through the trabeculations, relative to WT. Whole-mount PECAM1 immunostaining
of E9.0 WT and DT embryos. (I) WT embryo imaged at the heart level, showing normal arteries at the first (green arrow) and second branchial arches (blue arrow; DA, red
arrow). (J) DT embryo imaged at the heart level, showing the presence of a fully formed artery at the first branchial arch (blue arrow) but only a very reduced or nonexistent
artery at the second branchial arch (green arrow; DA, red arrow).
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increased by 35% (Figure 4B). Apoptosis analysis revealed that
even though the frequency of apoptotic DT arterial ECs is almost
double of that of their WT counterparts, it remains at the relatively
low level of 4.7% (Figure 4C). It appears thus that aortic
hypertrophy could be due to a defect in the migration of ECs from
the DA to form the intersomitic vessels, as fewer of the intersomitic
spaces in the DT embryos were vascularized at E8.5 (Figure 4E)
and E9.5 (Figure 4G) as compared with the wild-type (Figure
4D,F). These results indicate that the ECs are probably migrating
dorsally at a slower pace or in reduced numbers, therefore
accumulating in the DA and contributing to its enlargement.
Furthermore, mutant embryos showed a marked decrease in the
branching of the blood vessels. This feature was most prominent in
the cephalic region (Figure 4H,I).
mDll4 overexpression and accumulation of extracellular matrix
Degradation of the extracellular matrix is a crucial step to the
initiation of cell migration.24 With the observation of reduced
endothelial cell migration, we investigated the possibility of excess
matrix deposition or reduced degradation. Fibronectin and, to a
lesser extent, laminin, were more abundant around the dorsal aorta
of the mutant embryos (Figure 5A-L). We next tested if the increase
in matrix proteins was the result of higher expression or reduced
degradation. RT-PCR results indicated that there is an increase in
expression of fibronectin, laminin and collagen 1 and 4, and a
decrease in the expression of matrix degrading enzymes MMP1, -2,
and -9 (Figure 5M). Tissue inhibitors of metalloproteinases (TIMPs)
are inhibitors of matrix metalloproteinases (MMPs)25 and therefore
could be responsible for the decrease in the expression of MMPs.
However, the expression levels of TIMP-1, -2 and -3 were not
significantly altered in DT embryos (Figure 5M).
mDll4 overexpression and induction of Notch effectors
Dll4 mutant embryos reveal arterialization of all vessels defined by the
expression of Notch1, Hey1, EphrinB2, and Connexin37. We hypoth-
esized that Dll4 is inducing Notch receptors and its downstream
effectors responsible for arterial phenotype. Real-time PCR analysis of
putative candidate genes on FACS sorted ECs from WT and DT
embryos at 9 to 11 somite stage (Figure 5N) like in situ hybridization
data, showed induction of mDll4 (3.6-fold), and of the Notch effectors,
Figure 3. Arterial markers are expressed in all endothelial cells while venous markers are absent in E9.0 DT embryos in situ hybridization. (A,D) hey1 mRNA,
(B,E) notch1 mRNA. The Notch markers tested show concomitant expression in the aortae (DA) and ACV of DT embryos. Control embryos (D,E) only show expression of these
genes in the endothelium of the aortae. (C,F) flk1 mRNA shows lowered expression in the DT embryos. (G,J) ephrin-b2 mRNA, (H,K) connexin37 mRNA. The arterial
endothelial specific markers tested show concomitant expression in the aortae and ACV of DT embryos. Control embryos (J,K) only show expression of these genes in the
endothelium of the aortae. (I,L) eph-B4 mRNA is not detectable in the ACV of DT embryos despite being detected in the ACV of control embryos (L).
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the hairy/enhancer-of-split homologues Hey1, Hey2, and Hes5 in DT.
EphrinB2 was also up-regulated in Dll4 mutant embryos consistent with
the in situ hybridization results. Expression of the venous-specific
EphB4 receptor was down-regulated nearly 2-fold. The VEGF and
Notch pathways appear to regulate each other. Dll4 expression itself is
regulated by VEGF signaling,26 conversely Dll4 signaling inhibits
VEGF function in ECs in vitro.18 Endothelial cells sorted from DT
embryos were examined by RT-PCR for the expression of various
components of VEGF pathway. In particular VEGFR2 (flk1) had a
4-fold reduction, while VEGF R1 (flt1) was found to be up-regulated
7.2-fold (Figure 5N). In addition Neuropillin-2, a coreceptor for VEGF,
was also down-regulated in response to mDll4 over-expression, thus
contributing to a reduction of VEGF signaling. VEGF-A expression
levels were measured on whole embryo lysates and found to be not
significantly altered in the DT embryos. The significance of increased
expression (2.9-fold) of VE-cadherin (Figure 5N), a cell-to-cell ho-
mophilic adhesion molecule27 may also contribute to the mutant
phenotype. Endothelial cell guidance, as well as neuronal cell guidance,
is a genetically regulated process, under control of several signaling
systems. Among these there are several key genes known as regulators
of intersomitic blood vessel formation and guidance, such as Robo4,
Unc5b, and PlexinD1.28,29 In DT embryos Robo4 expression was
down-regulated nearly 2-fold (Figure 5N). Unc5b is a cognate receptor
for Netrin1, which acts as a inhibitor of vessel branching.30 In DT
Figure 4. Proliferation of arterial ECs is decreased in DT embryos. (A) BrdU incorporation studies show 16% of ECs per aortic cross-section of DT embryo are proliferating,
compared with 28% in WT embryos (P  .01). Number of ECs per aortic cross-section is increased in DT embryos. (B) In WT embryos there are on average 8.5 ECs per aortic
cross-section, in DT embryos there are 11.5 ECs, representing a 35% increase (P  .01). Apoptosis of arterial ECs is increased in DT embryos. (C) In WT embryos, on
average, 2.6% of arterial ECs are apoptotic, in DT embryos, on average, that frequency is 4.7%, representing a 80% increase in arterial endothelial apoptosis frequency
(P  .01). Endothelial cell migration is delayed in DT embryos. Wholemount PECAM1 immunostaining of E8.5 and E9.5 WT and DT embryos. (D) WT embryo at E8.5. (E) DT
embryo at E8.5 showing a delay in the migration of ECs from the DA to form the intersomitic blood vessels, relative to control embryo (D). (F) WT embryo at E8.5. (G) DT
embryo at E9.5 showing a continued delay in the migration of ECs from the DA to form the intersomitic blood vessels, relative to control embryo (F). Angiogenic sprouting is
reduced in DT embryos (H) Cephalic region of WT embryo at E9.5. (I) DT embryo at E9.5 showing a lowered number of new blood vessel sprouts in cephalic region, relative to
control embryo.
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embryos Unc5b expression was up-regulated 2.8-fold (Figure 5N).
PlexinD1 is a semaphorin receptor normally expressed by intersomitic
vessels.28 It is also involved in mediating guidance of new intersomitic
vessels.19 In DT embryos, PlexinD1 expression was not significantly
altered from the WT embryos (Figure 5N).
Dll4 inhibited endothelial cell migration and tube formation
We intended to determine whether full-length Dll4 could mimic the
mDll4 embryonic gain-of-function phenotype. HUVECs tran-
siently transfected with a full-length Dll4 expression vector, or
vector alone, were sorted and studied for various functions
including migration and tube formation.
Confluent ECs were wounded by a single scrape with a
sterile plastic Pasteur pipette. Migration of cells into the cleared
zone was evaluated and quantified over 18 hours. Dll4-FL
expressing cells migrate poorly even in the presence of exog-
enous VEGF when compared with vector only transfected cells.
However the addition of soluble form of Dll4 reversed the effect
of Dll4-Fl leading to increased cell migration into the cell clear
zone (Figure 6A,B).
Dll4-FL or vector transfected ECs were tested in tube formation
assays using ECs placed on polymerized Matrigel to promote the
formation of tube like structures. Minimal amounts of tubes
were formed in the absence of growth factors, and abundant tube
formation was observed with the addition of VEGF. Dll4-FL
showed a reduction of tube formation even in the presence of
exogenous VEGF (Figure 6C). Soluble form of Dll4 nearly
completely abolished the inhibitory effect of Dll4-FL (Figure 6C).
Dll4-FL however had no significant effect on cell proliferation or
apoptosis (Figure 6C).
Dll4-FL or vector only expressing ECs were examined for
expression of selected genes. DLL4 was induced in cells trans-
fected with Dll4-FL expression vector (Figure 6E). In addition,
genes known to be regulated by Dll4-Notch indeed showed the
expected pattern of regulation, such as down-regulation of EphB4
and up-regulation of EphrinB2, Notch4, Hey1, and Hey2. In
addition, a pronounced induction of Fibronectin and reduction of
VEGFR2 was noted, in concordance with the results obtained in
ECs from DT embryos (Figure 6E).
Dll4 reduced vascularization and increased pericyte
recruitment of Matrigel plugs in vivo
To further demonstrate that Dll4 can directly modulate angiogenesis in
vivo, we performed a murine Matrigel plug experiment. Matrigel was
Figure 5. Extracellular matrix deposition around the dorsal aortae is increased in mDll4 overexpressing embryos: Immunofluorescence of cryosections from E8.5 DT
and control embryos. (A,C,D) Fibronectin deposition around the dorsal aorta of a WT embryo. (B,E,F) DT embryo section showing increased amount of fibronectin surrounding
the dorsal aorta, relative to control embryo. (G,I,J) Laminin deposition around the dorsal aorta of a WT embryo. (H,K,L) DT embryo section showing increased deposition of
laminin surrounding the dorsal aorta, forming a more defined layer relative to the patchier deposition seen in the control embryo. Matrix protein coding genes expression is
increased in mDll4 overexpressing embryos while matrix degrading enzymes coding genes are down-regulated. (M) RT-PCR results for Fibronectin, Laminin, Collagen-1, -4,
MMP1, 2, 9 and TIMP1, 2, and 3 compared with WT and DT ECs. (N) Transcriptional analysis of mDll4 overexpressing embryonic ECs. Notch pathway genes (Hey1, Hey2,
Hes5), arterial markers (Connexin37, EphrinB2), and cell-to-cell adhesion protein coding genes (VE-cadherin) are up-regulated as a consequence of Dll4 overexpression.
Venous marker (EphB4) and VEGF receptors Flk1 and Neuropillin2 are down-regulated while Flt is up-regulated. VEGF-A expression, measured from whole embryo lysates, is
not significantly altered in DT embryos. Robo4 is down-regulated, Unc5b is up-regulated and PlexinD1 is not significantly altered. Relative quantitative gene expression in DT
embryos compared with WT (n  3 per group). Values were normalized in relation to -actin expression. *P  .01.
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impregnated with VEGF and either 293T cell line–expressing full-
length Dll4-Fl, or vector alone. The matrigel-cell admixture was injected
into the ventral abdominal subcutaneous tissue of Balb/C nu/nu mice.
Matrigel plugs were harvested on day 6 and examined for vascular
density with PECAM/CD31 and pericytes with smooth muscle actin
localization (Figure 6F). VEGF containing plugs formed various stages
of vascular structures (6.5-fold more vessels compared with Matrigel
alone) including those with open lumen, and encased with pericytes.
Soluble Dll4 containing plugs formed more vascular structures (4.6-fold
increase compared with VEGF alone), but these vessels had no
appreciable lumen. In addition, whereas almost all VEGF-induced
vessels had recruited pericytes, only 22% vessels contained pericytes in
the presence of sDLL4 (Figure 6A). In sharp contrast, Matrigel plugs
containing 293T cells transfected with Dll4-FL had 53% fewer blood
vessels compared with vector alone, had rare branch points, and
contained large lumen. Furthermore, there was a 2.2-fold increase in
pericytes recruited to blood vessels in the presence of Dll4-FL compared
with vector alone (Figure 6G).
Figure 6. Dll4-FL inhibits EC migration. (A) HUVECs were transfected with expression vectors for Dll4-Fl or vector alone and sorted for transfected cells. Confluent cultures
of HUVECs were scraped with a plastic Pasteur pipette to produce a 3-mm–wide cell-free zone in the monolayer. The ability of the cells to migrate and close the wound was
assessed over 18 hours. Dll4-Fl inhibited the migration of ECs even in the presence of VEGF, while exogenous sDll4 abolished this inhibition. (B) Endothelial cell migration into
the cell free zone was quantitated using Bioquant Image Analysis (mean  SEM from triplicate wells in 2 repetition experiments). *P  .05 when Dll4-Fl is compared with
vector alone treated either with VEGF or sDll4-His. Dll4-Fl inhibits tubule formation in vitro. Photomicrographs were taken with a Nikon Plan Fluor, 0.17, 4/0.12 NA objective
and 10 eyepiece and processed with Image-Pro Plus 6.0 (Media Cybernetics, Bethesda, MD). (C) HUVECs were transfected with expression vectors for Dll4-Fl or vector
alone and sorted cells were cultured on standard Matrigel in growth factor–deficient conditions in triplicates in 2 independent experiments with either sDll4 or VEGF for
18 hours. Shown are representative pictures from triplicate wells repeated twice. Quantitative analysis for tube length and the number of junctions in various groups is
presented. *P  .05 compared with no growth factor. (D) HUVECs transfected with Dll4-Fl or vector alone were evaluated for cell proliferation (left panel) after 72 hours.
Apoptosis in serum-deprived conditions was measured after 24 hours, using annexin-V FITC (right panel). Dll4-Fl induces fibronectin and artery specific genes. (E) HUVECs
were transfected with expression vectors for Dll4-Fl or vector alone and sorted for transfected cells. Dll4 expression in Dll4-Fl transfected and sorted cells was assessed using
MabDll4-FITC. cDNA was analyzed by RT-PCR for the expression of various genes that are differentially regulated in venous and arterial ECs. GAPDH and -actin expression
was examined to document equal amount of cDNA in each group. Two independent experiments produced similar results. EphB4, EphrinB2 and -actin protein levels were
evaluated by immunoblotting (bottom right panel). sDll4 induces vessel response in murine Matrigel assay. (F) Matrigel lacking growth factor or impregnated with VEGF or
VEGF  sDll4-His were injected subcutaneously into Balb/C nu/nu mice. After 6 days, plugs were removed and processed in paraffin. Individual sections were stained with
H&E, and representative photographs at 20 magnification from triplicate plugs in 2 independent experiments are shown. Matrigel plugs were stained for PECAM/CD31, or
SMA. Photomicrographs were taken with an Olympus BX51 microscope with an Olympus UPlan FL, 0.17 20/0.5 NA dry objective mounted with a Retiga 2000R camera
(QImaging, Burnaby, BC) and processed with Image-Pro Plus 6.0 (Media Cybernetics). Quantitation of CD31, SMA positive cells was as in Figure 3. (G) Dll4-Fl induces fewer
vessels with increased SMA. 293T cells were transfected with expression vectors for Dll4-Fl or vector alone and sorted cells were implanted in standard Matrigel in growth
factor–deficient conditions in triplicates in 2 independent experiments. After 6 days, plugs were removed and processed in paraffin. Individual sections were stained with H&E,
and representative photographs at 20 magnification from triplicate plugs in 2 independent experiments are shown. Matrigel plugs were stained for PECAM/CD31, or SMA.
Photomicrographs were taken with an Olympus BX51 microscope with an Olympus UPlan FL, 0.17 20/0.5 NA dry objective mounted with a Retiga 2000R camera (QImaging)
and processed with Image-Pro Plus 6.0 (Media Cybernetics). Quantitation of CD31, SMA-positive cells was as in Figure 3.
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Discussion
Dll4 is the only known Notch ligand expressed on arterial endothelium,
in complementary fashion to Notch1 and Notch4. Loss-of-function
studies revealed that Dll4 is the ligand responsible for Notch signaling
activation in the developing vasculature of mice, leading to reduced and
collapsed DA, angiogenic remodeling defects, and loss of arterial
endothelial identity in a dosage-sensitive manner.10 To further the
understanding of Dll4 function in vascular development we produced
conditional overexpression transgenics.
Dll4 overexpression in the transgenic embryos led to arterialization
of the venous endothelium. In the mutant embryos, arterial specific
markers, including Ephrin-B2, are also expressed in veins. The resulting
vascular system showed premature fusion between arteries and veins
possibly from the loss of repulsive signal between arterial and venous
vascular bed. This phenotypic feature has also been seen in Dll4,10
Endoglin, and ALK131 knockout mutants.
The presence of arterio-venous malformations produces a
circulatory defect by blood flowing out of the heart through the DA
and back directly into the heart through the sinus venosus, thus
reducing perfusion, contributing to the mutant phenotype.
Overexpression of Dll4 also displays heart defects. The ven-
tricles of DT embryos show reduced trabeculation, with reduced
cardiomyocites in the inner layers of the trabeculae relative to the
ventricular wall. The atria also showed a marked dilation. The
outflow tract showed reduced cells within its cushions and absence
of the second branchial arch arteries. As the vascular defects
precede the initiation of the heartbeat, it is possible that some of the
defects are independent of defective blood flow.10
Analysis of proliferation rates of arterial ECs showed that there is
approximately a 50% decrease in proliferation rate of arterial ECs with,
on average, a 35% increase in the number of ECs per aortic cross-
section. The increased number of ECs explains the hyperplasia of the
DA in these embryos, which appears in contradiction to the observed
decrease in the proliferation rate of these cells. Endothelial apoptosis is
doubled on DT embryos, accounting for 4.7% of arterial ECs, again
contradicting the increase in the number of aortic ECs. The other
possibility for explaining the increase in the number of aortic ECs is
decreased endothelial migration. Endothelial cell migration into the
intersomitic spaces to form the intersomitic vessels is dependent on
attractive signals created by proangiogenic factors such as VEGF, which
are secreted by dorsal structures like the somites and the neural tube.32,33 In
situ hybridization and RT-PCR results show that the mutant embryos have
marked reduction in VEGFR2 expression. It is likely that the migration
delay observed in the formation of the intersomitic vessels of DT embryos
is due in part to decreased sensitivity to VEGF signaling. Altered
expression of Robo4 and Unc5b may also contribute to the mutant
phenotype.28-30 A decrease in the branching of cranial blood vessels was
also observed. Dll4-Notch pathway thus regulates vascular sprouts.34-36
The basal lamina needs to be dissolved before an endothelial cell can
initiate migration. We observed an increase in fibronectin deposition
around the DA and a slight increase in laminin deposition, which may
account for a more compacted basal lamina around the DAendothelium,
and reduced endothelial cell migration. RT-PCR results also indicate an
increase in the expression of Collagen1 and 4, and reduced expression
of matrix proteinases, MMP-1,-2, and 9. These findings were supported
by 2 independent methods, immunofluorescence and RT-PCR, both in
vivo in the transgenic embryos and in vitro in Dll4-FL transfected ECs.
Transcriptional analysis by RT-PCR shows that Dll4 regulates VEGF
signaling by up-regulating VEGF-R1 and down-regulating VEGF-R2.37
VEGF-R1 seems to act as a VEGF sink during embryonic vascular
development, both at the membrane and also as a soluble form.38,39
Down-regulation of Neuropillin-2, a coreceptor for VEGF may also
contribute to the reduction in VEGF function.40
Given the failure to obtain endothelial specific overexpression
with the ZEG-Dll4 conditional transgenics, the subsequent produc-
tion of tetO7-Dll4 mouse lines allowed us to ascertain whether the
defects observed in the DT embryos were indeed only derived from
homotypic interactions between Dll4 overexpressing ECs or some
form of secondary effect caused by ectopic Dll4 overexpression. As
endothelial-specific overexpression of Dll4 produced the same
cardiovascular phenotype, with lethality at the same stage in
development, we can attribute the cause of the cardiovascular
phenotype described in DT embryos to homotypic interactions at
the endothelial level.
In vitro work confirmed the results obtained with the
transgenic embryos indicating that Dll4-FL inhibits the migra-
tory phenotype induced in ECs by VEGF signaling, which is
reminiscent of the delayed growth of the intersomitic vessels of
DT embryos. Dll4-FL was also confirmed as being able to
inhibit branching angiogenesis and tubulogenesis induced by
VEGF, which is similar to what happens in the vasculature of the
cephalic region of DT embryo.
Dll4 has recently been shown to be an important modulator of
tumor growth. Studies with inhibitors of Dll4 have shown these to
produce a tumor vasculature that, while being more abundant, was
less mature and had markedly reduced perfusion leading to reduced
tumor growth.17,41,42 Dll4-FL expressing 293T cells, when im-
planted in Matrigel, produced fewer vessels which displayed
greater maturation, including larger lumen and abundant pericytes.
It is of importance that this phenotype is the opposite of what is
observed in mDll4	/	 embryos, where there is increased pro-
liferation with decreased number of EC per aortic cross-sections.
In the mDll4	/	 embryos aortic ECs migrate more in response
to VEGF gradients and create more new branches, leaving a
severely reduced and collapsed DA (unpublished data). Recent
works in zebrafish43,44 also confirm this phenotype and the
interplay with VEGF in vivo.
In sum, Dll4 appears to work as a negative regulator of
angiogenesis, antagonizing VEGF function by negatively regulat-
ing VEGF receptor expression. Dll4 negatively regulates endothe-
lial cell proliferation, migration and vessel branching and posi-
tively regulates extracellular matrix deposition and endothelial
cell-to-cell adhesion. Dll4 is a VEGF responsive gene26 and acts as
negative regulator of VEGF signaling. This interplay reveals a
mechanism whereby ECs make continuous dosage dependent
decisions on whether to carry out effective expansion of the
vascular network or become quiescent contributing to the matura-
tion of the blood vessels, a critical balance in the formation and
remodeling of the vascular system.
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